share_log

AstraZeneca | 6-K: Voydeya Recommended for Approval in the Eu by CHMP as Add-On Treatment to Ravulizumab or Eculizumab for Adults with PNH Who Have Residual Haemolytic Anaemia

AstraZeneca | 6-K: Voydeya Recommended for Approval in the Eu by CHMP as Add-On Treatment to Ravulizumab or Eculizumab for Adults with PNH Who Have Residual Haemolytic Anaemia

阿斯利康 | 6-K:CHMP建议欧盟批准Voydeya作为Ravulizumab或Eculizumab的附加疗法用于患有残余溶血性贫血的PNH成人
SEC announcement ·  02/26 06:25
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息